We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-6.04%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.45B
AUM Growth
-$206M
Cap. Flow
+$38.7M
Cap. Flow %
2.66%
Top 10 Hldgs %
69.2%
Holding
57
New
2
Increased
7
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$40.5M
2
GERN icon
Geron
GERN
+$17M
3
VERA icon
Vera Therapeutics
VERA
+$14.3M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.48M
5
CLDX icon
Celldex Therapeutics
CLDX
+$4.6M

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$12.8M
2
EPIX
ESSA Pharma
EPIX
+$10.6M
3
WHWK
Whitehawk Therapeutics
WHWK
+$10.2M
4
LRMR icon
Larimar Therapeutics
LRMR
+$4.31M
5
MREO
Mereo BioPharma
MREO
+$4.02M

Sector Composition

Rank Sector Weight
1 Healthcare 84.74%
2 Financials 11.77%
3 Materials 3.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WHWK
26
Whitehawk Therapeutics
WHWK
$201M
$13.1M 0.9%
772,416
-530,974
-41% -$10.2M
MRUS
27
DELISTED
Merus
MRUS
$11.7M 0.8%
442,000
– –
IOVA icon
28
Iovance Biotherapeutics
IOVA
$1.94B
$10.9M 0.75%
655,057
+354,057
+118% +$5.48M
BOLT icon
29
Bolt Biotherapeutics
BOLT
$7.59M
$10.6M 0.73%
193,565
– –
UTRS
30
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$9.97M 0.69%
110,783
– –
LEGN icon
31
Legend Biotech
LEGN
$3.69B
$8.88M 0.61%
244,375
– –
CDXS icon
32
Codexis
CDXS
$156M
$8M 0.55%
388,144
– –
ZLAB icon
33
Zai Lab
ZLAB
$2.07B
$7.99M 0.55%
181,577
+6,578
+4% +$318K
TERN
34
DELISTED
Terns Pharmaceuticals
TERN
$7.95M 0.55%
2,675,133
– –
DSGN icon
35
Design Therapeutics
DSGN
$849M
$7.7M 0.53%
476,589
-54,402
-10% -$833K
ALGS icon
36
Aligos Therapeutics
ALGS
$29.3M
$7.63M 0.53%
141,881
– –
OLMA icon
37
Olema Pharmaceuticals
OLMA
$1.01B
$7.2M 0.5%
1,689,515
– –
SERA icon
38
Sera Prognostics
SERA
$78.3M
$7.03M 0.48%
1,856,011
– –
BLU
39
DELISTED
BELLUS Health Inc.
BLU
$7M 0.48%
1,017,152
– –
ARWR icon
40
Arrowhead Research
ARWR
$12.3B
$6.32M 0.44%
137,411
– –
NKTX icon
41
Nkarta
NKTX
$157M
$5.83M 0.4%
512,225
– –
DYN icon
42
Dyne Therapeutics
DYN
$4.89B
$5.57M 0.38%
577,642
– –
STSA
43
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$4.68M 0.32%
1,232,394
– –
MREO
44
Mereo BioPharma
MREO
$48.4M
$4.25M 0.29%
3,795,225
-3,111,964
-45% -$4.02M
DICE
45
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$3.12M 0.21%
163,136
-163,136
-50% -$2.91M
CMPX icon
46
Compass Therapeutics
CMPX
$340M
$2.74M 0.19%
2,000,000
– –
QTTB icon
47
Q32 Bio
QTTB
$491M
$2.59M 0.18%
47,397
– –
ASLN
48
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$2.56M 0.18%
71,023
– –
GRCL
49
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$2.24M 0.15%
961,359
– –
ZYME icon
50
Zymeworks
ZYME
$1.73B
$1.87M 0.13%
286,064
– –
1
2
3

Similar funds

FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return
KOC
Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Vivo Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Vivo Capital held 57 positions worth $1.45B, down 12% from $1.66B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Vivo Capital's Q1 2022 filing shows 2 new, 7 increased, 7 reduced and 3 closed positions. Its largest new stake was Geron: 15,238,095 shares worth $20.7M. The largest sale was Harmony Biosciences, an estimated $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier, followed by Financials and Materials.

  • Vivo Capital's largest Q1 2022 buy was Geron: 15,238,095 shares worth $20.7M.
  • Vivo Capital added most to Sierra Oncology, Inc. Common Stock in Q1 2022, an estimated $40.5M increase.
  • Vivo Capital's biggest Q1 2022 reduction was Harmony Biosciences, cutting an estimated $12.8M.
  • Vivo Capital fully exited ESSA Pharma in Q1 2022, selling an estimated $10.6M.
  • Vivo Capital's ten largest holdings make up 69% of its $1.45B portfolio in Q1 2022.
  • Vivo Capital opened 2 new positions and closed 3 in Q1 2022.
  • Vivo Capital's portfolio value fell 12% quarter-over-quarter to $1.45B.

Based on Vivo Capital's 13F filing for Q1 2022, filed 13 May 2022.